prikaz prve stranice dokumenta HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients
  Download
PDF 3.96 MB
Scientific paper - Original scientific paper
HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients
Biomedicines, 10 (2022), 7; 1668. https://doi.org/10.3390/biomedicines10071668
Klobučar, Iva; Degoricija, Vesna; Potočnjak, Ines; Trbušić, Matias; Pregartner, Gudrun; Berghold, Andrea; Fritz-Petrin, Eva; Habisch, Hansjörg; Madl, Tobias; Frank, Saša

Cite this document

Klobučar, I., Degoricija, V., Potočnjak, I., Trbušić, M., Pregartner, G., Berghold, A. ... Frank, S. (2022). HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients. Biomedicines, 10. (7). doi: 10.3390/biomedicines10071668

Klobučar, Iva, et al. "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients." Biomedicines, vol. 10, no. 7, 2022. https://doi.org/10.3390/biomedicines10071668

Klobučar, Iva, Vesna Degoricija, Ines Potočnjak, Matias Trbušić, Gudrun Pregartner, Andrea Berghold, Eva Fritz Petrin, Hansjörg Habisch, Tobias Madl and Saša Frank. "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients." Biomedicines 10, no. 7 (2022). https://doi.org/10.3390/biomedicines10071668

Klobučar, I., et al. (2022) 'HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients', Biomedicines, 10(7). doi: 10.3390/biomedicines10071668

Klobučar I, Degoricija V, Potočnjak I, Trbušić M, Pregartner G, Berghold A, and sur.. HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients. Biomedicines [Internet]. 2022 July 11 [cited 2024 October 25];10(7). doi: 10.3390/biomedicines10071668

I. Klobučar, et al., "HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients", Biomedicines, vol. 10, no. 7, July 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:642691. [Accessed: 25 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients
AuthorIva Klobučar
AuthorVesna Degoricija
AuthorInes Potočnjak
AuthorMatias Trbušić
AuthorGudrun Pregartner
AuthorAndrea Berghold
AuthorEva Fritz-Petrin
AuthorHansjörg Habisch
AuthorTobias Madl
AuthorSaša Frank
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
The prognostic value of the subset of high-density lipoprotein (HDL) particles containing apolipoprotein (apo)A-II (HDL-apoA-II) in acute heart failure (AHF) remains unexplored. In this study, baseline serum levels of HDL-apoA-II (total and subfractions 1–4) were measured in 315 AHF patients using NMR spectroscopy. The mean patient age was 74.2 ± 10.5 years, 136 (43.2%) were female, 288 (91.4%) had a history of cardiomyopathy, 298 (94.6%) presented as New York Heart Association class 4, and 118 (37.5%) patients died within 1 year after hospitalization for AHF. Multivariable Cox regression analyses, adjusted for age and sex as well as other clinical and laboratory parameters associated with 1-year mortality in the univariable analyses, revealed a significant inverse association of HDL-apoA-II (hazard ratio (HR) 0.67 per 1 standard deviation (1 SD) increase, 95% confidence interval (CI) 0.47–0.94, p = 0.020), HDL2-apoA-II (HR 0.72 per 1 SD increase, 95% CI 0.54–0.95, p = 0.019), and HDL3-apoA-II (HR 0.59 per 1 SD increase, 95% CI 0.43–0.80, p < 0.001) with 1-year mortality. We conclude that low baseline HDL-apoA-II, HDL2-apoA-II, and HDL3-apoA-II serum levels are associated with increased 1-year mortality in AHF patients and may thus be of prognostic value in AHF.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 10, no. 7, 1668
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10071668
URN:NBNurn:nbn:hr:105:642691
Publication2022-07-11
Document URLhttps://www.mdpi.com/2227-9059/10/7/1668
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-03-01 16:49:30